中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.023 seconds)

    Phenoxybenzylamine derivatives as SSRIs
    11.
    发明授权
    Phenoxybenzylamine derivatives as SSRIs 失效
    苯氧基苄胺衍生物作为SSRIs

    公开(公告)号：US06610747B2

    公开(公告)日：2003-08-26

    申请号：US09941177

    申请日：2001-08-27

    Applicant: Mavis Diane Adam ,  Mark David Andrews ,  Mark Leonard Elliott ,  Geoffrey Edward Gymer ,  David Hepworth ,  Harry Ralph Howard, Jr. ,  Donald Stuart Middleton ,  Alan Stobie

    Inventor： Mavis Diane Adam ,  Mark David Andrews ,  Mark Leonard Elliott ,  Geoffrey Edward Gymer ,  David Hepworth ,  Harry Ralph Howard, Jr. ,  Donald Stuart Middleton ,  Alan Stobie

    IPC: A61K3118

    CPC classification number: C07D277/62 ,  A61K31/135 ,  A61K31/343 ,  A61K31/381 ,  A61K31/39 ,  A61K31/47 ,  C07C311/08 ,  C07C323/20 ,  C07C2602/08 ,  C07D215/20 ,  C07D239/74 ,  C07D307/87 ,  C07D327/06 ,  C07D333/54 ,  C07D333/72

    Abstract: A compound of general formula (I) wherein R1 and R2 are H, C1-C6alkyl or (CH2)d(C3-C6cycloalkyl) wherein d=0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; Z or Y is —SR3 and the other Z or Y is halogen or —R3; wherein R3 is C1-C4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; R4 and R5, which may be the same or different, are: A—X, wherein A=—CH═CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(═O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, optionally substituted independently by one or more R13; wherein R13 is hydroxy, C1-C4alkoxy, F, C1-C6alkyl, haloalkyl, haloalkoxy, —NH2, —NH(C1-C6alkyl) or —N(C1-C6alkyl)2.

    Abstract translation: 通式（I）的化合物，其中R 1和R 2是H，C 1 -C 6烷基或（CH 2）d（C 3 -C 6环烷基），其中d = 0,1,2或3; 或R 1和R 2与它们所连接的氮一起形成氮杂环丁烷环; Z或Y是-SR 3，另一个Z或Y是卤素或-R 3; 其中R 3是任选被氟取代的C 1 -C 4烷基; 除了R3不是CF3; 或Z和Y连接，使得与互连原子一起形成稠合的5至7元碳环或杂环，并且其中当Z和Y除碳原子之外形成杂环时，连接 含有一个或两个独立地选自氧，硫和氮的杂原子; R 4和R 5可以相同或不同，为：A-X，其中A = -CH = CH-或 - （CH 2）p - ，其中p为0,1或2; X是氢，F，Cl，Br，I，CONR6R7，SO2NR6R7，SO2NHC（= O）R6，OH，C1-4烷氧基，NR8SO2R9，NO2，NR6R11，CN，CO2R10，CHO，SR10，S（O）R9或SO2R10 ; 或含有1,2或3个选自N，S和O的杂原子的5-或6-元杂环，任选被一个或多个R 13独立地取代; 其中R 13是羟基，C 1 -C 4烷氧基，F，C 1 -C 6烷基，卤代烷基，卤代烷氧基，-NH 2，-NH（C 1 -C 6烷基）或-N（C 1 -C 6烷基）2。

    (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
    12.
    发明授权
    (Azetidin-1-ylalkyl) lactams as tachykinin antagonists 失效
    （氮杂环丁烷-1-基烷基）内酰胺作为速激肽拮抗剂

    公开(公告)号：US5968923A

    公开(公告)日：1999-10-19

    申请号：US798534

    申请日：1997-02-10

    Applicant: Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    Inventor： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    IPC: C07D205/08 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/451 ,  A61K31/4523 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/535 ,  A61K31/5377 ,  A61K31/54 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  A61P1/00 ,  A61P11/00 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  A61P43/00 ,  C07D205/04 ,  C07D205/06 ,  C07D205/085 ,  C07D211/76 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D451/06 ,  C07D521/00 ,  A61K401/06 ,  A61K413/14 ,  A61K451/02

    CPC classification number: C07D231/12 ,  C07D211/76 ,  C07D233/56 ,  C07D249/08 ,  C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D451/02

    Abstract: The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C.sub.3 -C.sub.7 cycloalkyl, aryl or C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl being optionally substituted by fluoro, COOH, --COO(C.sub.1 -C.sub.4 alkyl), C.sub.3 -C.sub.7 cycloalkyl, adamantyl, aryl or het.sup.1, and said C.sub.3 -C.sub.7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, fluoro, fluoro (C.sub.1 -C.sub.4) alkyl and fluoro (C.sub.1 -C.sub.4) Alkoxy; R.sub.1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo and trifluormethyl; R.sup.2 is --CO.sub.2 H, --CONR.sup.3 R.sup.4, --CONR.sup.5 (C.sub.3 -C.sub.7 cycloalkyl), --NR.sup.5 (C.sub.2 -C.sub.5 alkanoyl), --NR.sup.3 R.sup.4, --NR.sup.5 CONR.sup.5 R.sup.6, (C.sub.3 -C.sub.7 cycloalkyl-C.sub.1 -C.sub.4 alkyl)R.sup.5 N--, --NR.sup.5 COCF.sub.3, --NR.sup.5 SO.sub.2 CF.sub.3, --NR.sup.5 (SO.sub.2 C.sub.1 -C.sub.4 alkyl), --NR.sup.5 SO.sub.2 NR.sup.5 R.sup.6, --NR.sup.5 (SO.sub.2 aryl), --N(aryl) (SO.sub.2 C.sub.1 -C.sub.4 alkyl), --OR.sup.5, --O(C.sub.3 -C.sub.7 cycloalkyl), --SO.sub.2 NR.sup.5 R.sup.6, het.sup.3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C.sub.1 -C.sub.4 alkylene; X.sup.1 is a direct link or C.sub.1 -C.sub.6 alkylene; X.sup.2 is a direct link, CO, SO.sub.2, or NR.sup.5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. ##STR1##

    Abstract translation: PCT No.PCT / EP95 / 03054 Sec。 371日期1997年2月10日 102（e）日期1997年2月10日PCT提交1995年7月29日PCT公布。 出版物WO96 / 05193 日期：1996年2月22日本发明提供式（I）化合物及其药学上可接受的盐，其中R为C 3 -C 7环烷基，芳基或C 1 -C 6烷基，所述C 1 -C 6烷基，所述C 1 -C 6烷基任选 被氟，COOH，-COO（C1-C4烷基），C3-C7环烷基，金刚烷基，芳基或het1取代，所述C3-C7环烷基任选被1或2个独立地选自C 1 -C 4烷基，C 3 C 1 -C 4烷氧基，羟基，氟，氟（C 1 -C 4）烷基和氟（C 1 -C 4）烷氧基; R1是苯基，萘基，噻吩基，苯并噻吩基或吲哚基，各自任选被1或2个独立地选自C 1 -C 4烷基，C 1 -C 4烷氧基，卤素和三氟甲基的取代基取代; R2是-CO2H，-CONR3R4，-CONR5（C3-C7环烷基），-NR5（C2-C5烷酰基），-NR3R4，-NR5CONR5R6，（C3-C7环烷基-C1-C4烷基）R5N-，-NR5COCF3， NR5SO2CF3，-NR5（SO2 C1-C4烷基），-NR5SO2NR5R6，-NR5（SO2芳基），-N（芳基）（SO2C1-C4烷基），-OR5，-O（C3-C7环烷基），-SO2NR5R6， 或（a），（b），（c），（d），（e），（f），（g）或（h） X是C 1 -C 4亚烷基; X1是直链或C1-C6亚烷基; X2是直接连接，CO，SO2或NR5CO; m为0,1或2; 以及用于制备含有这种衍生物的速激肽类似物的组合物中使用的中间体。

    3-aza and 3-oxa piperidone tachykinin antagonists
    13.
    发明授权
    3-aza and 3-oxa piperidone tachykinin antagonists 失效
    3-氮杂和3-氧杂哌啶酮速激肽拮抗剂

    公开(公告)号：US5846965A

    公开(公告)日：1998-12-08

    申请号：US788001

    申请日：1997-01-24

    Applicant: Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    Inventor： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    IPC: A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/5355 ,  A61P1/00 ,  A61P11/00 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  A61P25/28 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D403/06 ,  C07D413/06 ,  A61K31/395 ,  C07D205/04 ,  C07D243/08 ,  C07D403/14

    CPC classification number: C07D403/06 ,  C07D413/06

    Abstract: Compounds of the formula: ##STR1## wherein: X is O, NH or NR.sup.1 ; R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4)alkyl, aryl or aryl (C.sub.1 -C.sub.4)alkyl; wherein the C.sub.1 -C.sub.6 alkyl group is optionally substituted by fluorine and the C.sub.3 -C.sub.7 cycloalkyl or C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4 )alkyl group is optionally substituted in the cycloalkyl ring by up to two substituents each independently selected from halo, C.sub.1 -C.sub.4 alkoxy or halo(C.sub.1 -C.sub.4)alkoxy; R.sup.2 is phenyl optionally substituted with one or two halo substituents, indolyl or thienyl; R.sup.3 is NH.sub.2, --NR.sup.4 SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --NR.sup.4 SO.sub.2 aryl, --NR.sup.4 CO(C.sub.1 -C.sub.6 alkyl), --NR.sup.4 CO aryl or a 5 to 7-membered N-linked cyclic group incorporating W in the ring wherein W is O, NR.sup.5, CH(OH), CHCO.sub.2 H, CHN(R.sup.4).sub.2, CHF, CF.sub.2, C.dbd.O or CH.sub.2 ; R.sup.4 is H or C.sub.1 -C.sub.6 alkyl; R.sup.5 is H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.6)alkyl, C.sub.2 -C.sub.6 alkanoyl, C.sub.4 -C.sub.8 cycloalkanoyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.2 -C.sub.6)alkanoyl, aryl CO--, C.sub.1 -C.sub.6 alkyl SO.sub.2 --, C.sub.3 -C.sub.7 cycloalkyl SO.sub.2 --, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.6)alkyl SO.sub.2 --, aryl-SO.sub.2 -- or (R.sup.6).sub.2 NSO.sub.2 --, wherein each R.sup.6 is independently H or C.sub.1 -C.sub.4 alkyl or the two groups may be joined to form with the nitrogen atom to which they are attached, a pyrrolidinyl, piperidino, morphlino or piperazinyl group; m is 0, 1 or 2 with the proviso that m is not 0 when W is NR.sup.5, C.dbd.O, or O; and n is an integer of from 1 to 4; are neurokinin receptor antagonists of utility in the treatment of a variety of medical conditions including urinary incontinence, asthma and related conditions.

    Abstract translation: 下式的化合物：其中：X是O，NH或NR1; R1是C1-C6烷基，C3-C7环烷基，C3-C7环烷基（C1-C4）烷基，芳基或芳基（C1-C4）烷基; 其中C 1 -C 6烷基任选被氟取代，并且C 3 -C 7环烷基或C 3 -C 7环烷基（C 1 -C 4）烷基任选在环烷基环中被至多两个各自独立地选自卤素， C4烷氧基或卤代（C1-C4）烷氧基; R2是任选被一个或两个卤素取代基取代的苯基，吲哚基或噻吩基; R 3是NH 2，-NR 4 SO 2（C 1 -C 6烷基），-NR 4 SO 2芳基，-NR 4 CO（C 1 -C 6烷基），-NR 4 CO芳基或在其中W为W的5至7元N-连接的环状基团 O，NR 5，CH（OH），CHCO 2 H，CHN（R 4）2，CHF，CF 2，C = O或CH 2; R4是H或C1-C6烷基; R5是H，C1-C6烷基，C3-C7环烷基，C3-C7环烷基（C1-C6）烷基，C2-C6烷酰基，C4-C8环烷酰基，C3-C7环烷基（C2-C6）烷酰基，芳基CO-， C 1 -C 6烷基SO 2 - ，C 3 -C 7环烷基SO 2 - ，C 3 -C 7环烷基（C 1 -C 6）烷基SO 2 - ，芳基-SO 2 - 或（R 6）2 NSO 2 - ，其中每个R 6独立地是H或C 1 -C 4烷基或 两个基团可以与它们所连接的氮原子结合形成吡咯烷基，哌啶子基，吗啉基或哌嗪基; m为0,1或2，条件是当W为NR5，C = O或O时，m不为0; n为1〜4的整数， 是用于治疗各种医学状况（包括尿失禁，哮喘和相关病症）的神经激肽受体拮抗剂。

    Compounds as delta opioid agonists
    17.
    发明授权
    Compounds as delta opioid agonists 失效
    化合物作为δ阿片激动剂

    公开(公告)号：US06200978B1

    公开(公告)日：2001-03-13

    申请号：US09261540

    申请日：1999-03-03

    Applicant: Graham Nigel Maw ,  Donald Stuart Middleton

    Inventor： Graham Nigel Maw ,  Donald Stuart Middleton

    IPC: A61K31496

    CPC classification number: C07D211/26 ,  C07D205/04 ,  C07D209/08 ,  C07D209/44 ,  C07D213/79 ,  C07D217/04 ,  C07D231/12 ,  C07D231/56 ,  C07D233/64 ,  C07D249/06 ,  C07D271/06 ,  C07D271/10 ,  C07D271/107 ,  C07D277/24 ,  C07D277/56 ,  C07D487/04

    Abstract: Compounds of the formula (I)—shown below—are described. The compounds are useful in the manufacture of a pharmaceutical composition for preventing or treating inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory function, gastrointestinal disorders such as functional bowel disease, functional GI disorders such as irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, non-ulcerogenic dyspepsia or others associated with disorders of motility or secretion, urogenital tract disorders such as incontinence, as analgesics for treating pain including non-somatic pain, or as immunosuppressants to prevent rejection in organ transplant and skin graft.

    Abstract translation: 描述下式（I）的化合物。该化合物可用于制备用于预防或治疗炎性疾病如关节炎，牛皮癣，哮喘或炎性肠病，呼吸功能障碍，胃肠道疾病的药物组合物 诸如功能性肠病，功能性胃肠疾病如肠易激综合征，功能性腹泻，功能性膨胀，功能性疼痛，非溃疡性消化不良或与运动性或分泌性障碍相关的其它功能性肠病，泌尿生殖道疾病如失禁等疾病，作为治疗用止痛剂 疼痛包括非躯体疼痛，或作为免疫抑制剂，以防止器官移植和皮肤移植排斥反应。

Patent Agency Ranking